• Molecular NameVildagliptin
  • SynonymEQUA; Galvus; Jalra; LAF 237; LAF237; NVP-LAF-237; NVP-LAF237; Xiliarx
  • Weight303.406
  • Drugbank_IDDB04876
  • ACS_NO274901-16-5
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)1.53
  • pkaN/A
  • LogD (pH=7, predicted)0.84
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-0.22
  • LogSw (predicted, AB/LogsW2.0)33.42
  • Sw (mg/ml) (predicted, ACD/Labs)5.51
  • No.of HBond Donors2
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds4
  • TPSA76.36
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA new oral anti-hyperglycemic agent (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability85.0
  • Protein binding9.3
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmMainly hydrolysis to inactive metabolite; CYP450 not appreciably involved
  • Half life2~3 h
  • ExcretionRenal
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A